Dr. Schmitt studied Biology at the University of Heidelberg. In 2008, he obtained his Ph.D. at the German Cancer Research Centre (DKFZ) as part of the Infection and Cancer research program. Dr. Schmitt continued his research in the same program as a post-doctoral fellow until 2014. His research focus was on the association between human papillomaviruses (HPV) and cancer of the uterine cervix, as well as the development of biomolecular technologies for improved cervical cancer precursor screening. Dr. Schmitt is an author of more than 45 peer-reviewed papers and holds a number of patents. Dr. Schmitt has been a part of GATC Biotech’s R&D team since 2014. His main tasks include evaluation and implementation of the latest sequencing technologies, as well as development and optimisation of products and processes. Dr. Schmitt is also heavily involved in GATC Biotech’s research efforts for publicly funded projects, such as NanoDiaMed and SysClad.

Association between human papillomaviruses (HPV) and cancer of the uterine cervix, as well as the development of biomolecular technologies for improved cervical cancer precursor screening.